×

VivoCAR™ Anti-hCSPG4 h(CD8H&TM-Megf10) CAR-M, mRNA-LNP (XS-0826-XL6)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Formulated in advanced lipid nanoparticles, synthetic mRNA drives expression of a CSPG4-directed CAR. Featuring a human CD8 hinge-transmembrane backbone and Megf10 domain, it potentates macrophage-driven targeting of solid tumors.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

CAR Information

  • Target Species
  • Human
  • Host
  • Mouse
  • CAR Construction
  • h(CD8H&TM-Megf10)
  • CAR Generation
  • 1st Generation Macrophage-Specific CAR
  • CAR Signaling Description
  • A human CD8alpha-derived hinge and transmembrane region fused to the intracellular domain of human Megf10.

CAR mRNA Properties

  • Cap
  • Cap 1
  • PolyA
  • Segmented PolyA
  • Product Type
  • CAR mRNA LNP
  • Lipid Mixture
  • Utilizes a proprietary lipid platform composed of ionizable lipid, cholesterol, helper phospholipid, and PEG-lipid.
  • Concentration
  • Lot specific
  • Buffer
  • The formulation is buffered in either Phosphate-Buffered Saline (PBS) or a citrate buffer containing 10% sucrose to maintain lipid nanoparticle stability and prevent aggregation during freeze-thaw cycles.
  • Storage
  • Maintain at -80°C. Avoid repeated freeze-thaw cycles to preserve mRNA integrity and LNP size distribution.
  • Handling
  • Thaw slowly on ice prior to use. Avoid vigorous vortexing; gently invert the vial to mix in order to preserve LNP integrity.

mRNA Quality Control

  • OD260/280
  • PASS
  • Agarose Gel Mobility
  • PASS
  • IVT Vector Sequencing
  • PASS
  • IVT Vector Enzyme Digestion
  • PASS
  • mRNA Transfection Efficiency
  • PASS
  • CAR Expression after mRNA Transfection
  • PASS

Target Information

  • Target
  • hCSPG4
  • Gene Name
  • Chondroitin sulfate proteoglycan 4, HMW-MAA, NG2
  • Introduction
  • Cell surface proteoglycan involved in tumor cell motility, invasion, and angiogenesis; highly expressed in aggressive solid tumors.
  • Related Diseases
  • Melanoma, triple-negative breast cancer, glioblastoma, soft tissue sarcoma

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for VivoCAR™ Anti-hCSPG4 h(CD8H&TM-Megf10) CAR-M, mRNA-LNP (XS-0826-XL6). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.